Corden Pharma vs Kaneka Eurogentec: CDMO Comparison

How does Corden Pharma compare to Kaneka Eurogentec?

As of Aug 2026, Corden Pharma: 5 FDA inspections (including 1 NAI, 4 VAI and 0 OAI), 17 EMA/MHRA GMP certificates. Signal Score 83.1. Kaneka Eurogentec: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 4 EMA/MHRA GMP certificates. Signal Score 81.6. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Corden Pharma and Kaneka Eurogentec on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score
83/100
Quality (FDA + GMP)
99/100
FDA inspections
5
— NAI / VAI / OAI
1 / 4 / 0
FDA warning letters
0
EMA GMP certificates (active)
17
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
mRNA, Oligonucleotide, Biologics
Seraing, BE
Signal Score
82/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
0 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
4
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
mRNA, Plasmid, Oligonucleotide

Key differences

  • Corden Pharma has more FDA inspections on record (5 vs 1) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Corden Pharma has materially broader EMA GMP coverage (17 active certificates vs 4) — stronger EU footprint.

Across the cross-modality scorecard, Corden Pharma carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: Corden Pharma vs Kaneka Eurogentec

How does Corden Pharma compare to Kaneka Eurogentec?

On CDMO Signal's composite Signal Score, Corden Pharma is 83/100 and Kaneka Eurogentec is 82/100; Corden Pharma has 5 FDA inspections on record vs 1 for Kaneka Eurogentec; European coverage is 17 active EMA+MHRA certificates for Corden Pharma vs 4 for Kaneka Eurogentec. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Corden Pharma or Kaneka Eurogentec?

Both Corden Pharma and Kaneka Eurogentec maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Corden Pharma has 5 FDA inspections on record; Kaneka Eurogentec has 1.

How do Corden Pharma and Kaneka Eurogentec compare on European GMP coverage?

Corden Pharma holds 17 active EMA GMP certificates and 0 MHRA / UK certificates. Kaneka Eurogentec holds 4 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

Corden Pharma carries a Signal Score of 83/100 and Kaneka Eurogentec carries 82/100 — essentially tied for Corden Pharma. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Corden Pharma and Kaneka Eurogentec for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.